|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Sequential Integrated Screen, Part 1
Test Code16131
CPT Codes
81508<br /> **This test is not available for California patient testing.** <br /> **This code is for non-New York clients only. For New York patient testing, use code 16974.**
Includes
PAPP-A, hCG
High risk results will be reported with a complete interpretation in the first trimester. Values not interpreted as high risk in the first trimester will be incorporated with the second trimester values as part of the integrated testing process.
High risk results will be reported with a complete interpretation in the first trimester. Values not interpreted as high risk in the first trimester will be incorporated with the second trimester values as part of the integrated testing process.
Preferred Specimen
1.5 mL serum
Minimum Volume
0.8 mL
Instructions
Sequential Integrated Screen: Used to determine risk of delivering a child with Down Syndrome, Trisomy 18, or Open NTD. This test is performed using two specimens collected at separate times. Part 1 is performed in the first trimester between 10.0 and 13.9 weeks of pregnancy and includes a practitioner-collected nuchal translucency measurement. Part 2 is performed in the 2nd trimester between 14.0 and 22.9 weeks of pregnancy.
Collect between 10.0 weeks to 13.9 weeks. Must complete patient demographic information using the "Maternal Serum Screen Requisition".
Additional Information: NT measurement, when provided by the physician, will be used for additional interpretation.
Collect between 10.0 weeks to 13.9 weeks. Must complete patient demographic information using the "Maternal Serum Screen Requisition".
Additional Information: NT measurement, when provided by the physician, will be used for additional interpretation.
Transport Container
Plastic screw-cap vial
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 14 days
Refrigerated: 14 days
Frozen: 28 days
Refrigerated: 14 days
Frozen: 28 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis
Methodology
Chemiluminescence (CL) • Immunoassay (IA)
FDA Status
*PAPP-A Component only: This test was performed using a kit that has not been cleared or approved by the FDA. The analytical performance characteristics of this test have been determined by Quest Diagnostics. This test should not be used for diagnosis without confirmation by other medically established means.
Setup Schedule
Set up: Mon-Sat; Report available: 4-6 days
Reference Range
See Laboratory Report
Clinical Significance
To assess maternal risk for carrying a fetus with Down Syndrome (Trisomy 21), Trisomy 18, or a neural tube defect. These types of tests are standard-of-care in obstetrics.
Performing Laboratory
| Quest Diagnostics Nichols Institute-San Juan Capistrano, CA |
| 33608 Ortega Highway |
| San Juan Capistrano, CA 92675-2042 |
